icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
GS-6620, A Liver-Targeted Nucleotide Prodrug, Exhibits Antiviral Activity and Favorable Safety Profile Over 5 Days in Treatment Na´ve Chronic HCV Genotype 1 Subjects
 
 
  Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
 
E. Lawitz1, J. Hill2, T. Marbury3, L. Hazan4, D. Gruener5, L. Webster6, R. Majauskas7, R. Morrison8, M. DeMicco9, P. German10, D. Stefanidis10, E. Svaroskaia10, S. Arterburn10, A. Ray10, S. Rossi10, J. McHutchison10, M. Rodriguez-Torres11 1Alamo Medical Research, San Antonio, TX, 2Avail Clinical Research, Deland, FL, 3Orlando Clinical Research Center, Orlando, FL, 4Axis Clinical Trials, Los Angeles, CA, 5CRI Worldwide, Philadelphia, PA, 6Lifetree Clinical Research, Salt Lake City, UT, 7University of Florida, Gainesville, FL, 8Comprehensive Clinical Development, Tacoma, WA, 9Advanced Clinical Research, Anaheim, CA, 10Gilead Sciences, Foster City, CA, 11Fundacion de Investigacion de Diego, San Juan, PR

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif